Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Reporter's Eye: 5
April 18, 2005
- MEDICAL DEVICE NEWS IN BRIEF
April 18, 2005
- NEW PRODUCTS
April 18, 2005
- Tanabe Seiyaku Working to Strengthen Quality Assurance System
April 18, 2005
- Nu-lotan Shows High Evidence Scores in Clinical Studies
April 18, 2005
- The Reporter's Eye: 3
April 11, 2005
- MPC Adds SP Codes to All Its Ethical Drugs
April 11, 2005
- Astellas Sets Out with 2,500 MRs in Japan
April 11, 2005
- OTC/HEALTH FOOD NEWS IN BRIEF
April 11, 2005
- Eisai Carries Out Organizational Restructuring
April 11, 2005
- NEW PRODUCYS
April 11, 2005
- Toho to Tie Up with 6 Regional Wholesalers
April 11, 2005
- Average Foreign Price Adjustment Rule Comes Under Criticism Again
April 11, 2005
- IMS to Boost Consulting Business to 20% of Sales
April 11, 2005
- Schering-Plough KK Aims for Sales of \100 Bil. by FY2010
April 11, 2005
- BUSINESS NEWS IN BRIEF
April 11, 2005
- NEW PRODUCYS
April 11, 2005
- Roche's Anticancer Agent Tarceva Approved in Switzerland
April 11, 2005
- Amended PAL Goes into Full Effect
April 11, 2005
- Self-injection to Be Allowed for INF a, Etanercept
April 11, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…